Immunology of Osteoporosis: A Mini-Review

@article{Pietschmann2015ImmunologyOO,
  title={Immunology of Osteoporosis: A Mini-Review},
  author={P. Pietschmann and D. Mechtcheriakova and A. Meshcheryakova and U. F{\"o}ger-Samwald and I. Ellinger},
  journal={Gerontology},
  year={2015},
  volume={62},
  pages={128 - 137}
}
Osteoporosis is a major cause of fractures and associated morbidity in the aged population. The pathogenesis of osteoporosis is multifactorial; whereas traditional pathophysiological concepts emphasize endocrine mechanisms, it has been recognized that also components of the immune system have a significant impact on bone. Since 2000, when the term ‘osteoimmunology' was coined, novel insights into the role of inflammatory cytokines by influencing the fine-tuned balance between bone resorption… Expand

Paper Mentions

Is osteoporosis an autoimmune mediated disorder?
TLDR
This review shall attempt to provide a comprehensive overview of existing research examining the role played by autoantibodies in osteoporosis in order to determine the potential for further research in this area. Expand
Inflammation, Oxidative Stress, and Bone in Chronic Kidney Disease in the Osteoimmunology Era
TLDR
A general view of the progresses in the field of bone research and their potential clinical implications is provided, with emphasis on the links with inflammation and the connections to osteoimmunology and chemokines. Expand
Osteoporosis: Pathophysiology and therapeutic options
TLDR
An overview on currently available osteoporosis medications including antiresorptive and bone forming drugs is provided and an outlook on potential future treatment options is given. Expand
Postmenopausal Osteoporosis : A Mini Review
Postmenopausal osteoporosis is an oestrogen deficiency-induced, systemic skeletal disease that affects the quality of life of patients once severe complications develop. The imbalance inExpand
PATHOPHYSIOLOGY AND THERAPEUTIC OPTIONS
Osteoporosis is a metabolic bone disease that, on a cellular level, results from osteoclastic bone resorption not compensated by osteoblastic bone formation. This causes bones to become weak andExpand
Bone, inflammation and the bone marrow niche in chronic kidney disease: what do we know?
  • S. Mazzaferro, G. Cianciolo, +6 authors G. La Manna
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2018
TLDR
An integrated view of bone, which includes the BM niche, now seems necessary in order to understand the complex clinical entity of chronic kidney disease-mineral and bone disorders and its cardiovascular burden. Expand
Chronic Psychological Stress as a Risk Factor of Osteoporosis.
TLDR
Active mastication, proven to be an effective stress-coping behavior, can attenuate stress-induced neuroendocrine responses and ameliorate stress- induced bone loss and may represent a useful approach in preventing and/or treating chronic stress-associated osteoporosis. Expand
Adipokines and Chronic Rheumatic Diseases: from Inflammation to Bone Involvement
Besides its well-known role as energy storage tissue, adipose tissue is a biologically active tissue that can also be considered as an endocrine organ, as it is able to secrete adipokines. TheseExpand
Does systemic inflammation and immune activation contribute to fracture risk in HIV?
TLDR
The findings suggest an important role for immune-mediated mechanisms in the pathogenesis of low BMD in HIV along with the immunocentric basis of bone loss in HIV alongside supporting the benefits of earlier ART initiation. Expand
Interaction between bone and immune cells: Implications for postmenopausal osteoporosis.
TLDR
In addition to the direct negative influence of estrogen-deficiency on bone, immune cell alterations contribute to the pathogenesis of postmenopausal osteoporosis. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 81 REFERENCES
Osteoporosis: now and the future
TLDR
Novel treatment strategies have been developed that aim to inhibit excessive bone resorption and increase bone formation and the most promising novel treatments include denosumab, a monoclonal antibody for receptor activator of NF-κB ligand; odanacatib, a specific inhibitor of the osteoclast protease cathepsin K; and antibodies against the proteins sclerostin and dickkopf-1, two endogenous inhibitors of bone formation. Expand
Biomolecular basis of the role of diabetes mellitus in osteoporosis and bone fractures.
TLDR
The aim of this review is to summarize the possible mechanisms through which diabetes may induce osteoporosis. Expand
Biologic therapies and systemic bone loss in rheumatoid arthritis.
TLDR
Improved knowledge of the association between cells and cytokines of the immune system and their relationship to bone remodeling has revealed several promising targets for the treatment of inflammatory bone loss in rheumatoid arthritis, and initiation of biologic therapies targeting inflammatory cytokines and/or lymphocyte activation is modified. Expand
The Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis
TLDR
The interconnection between bone turnover and the immune system and the implications thereof for physiological and pathological bone turnover are examined. Expand
Aging and bone loss: new insights for the clinician
TLDR
New evidence on the pathophysiology of age-related bone loss with emphasis upon the mechanism of action of current osteoporosis treatments is reviewed, including therapeutic approaches to osteoporeosis in the elderly that focus on thePathophysiology and potential reversal of adipogenic shift in bone. Expand
The role of interleukin-17 in bone metabolism and inflammatory skeletal diseases
TLDR
A better understanding of the role of IL-17 in skeletal systems warrants an advance in bone biology, as well as development of therapeutic strategies against bone-lytic diseases, such as rheumatoid arthritis and periodontitis. Expand
Advances in Osteoimmunology: Pathophysiologic Concepts and Treatment Opportunities
TLDR
A considerable number of investigations carried out over the past decade have identified critical proteins with osteoimmune functions including the pro-osteoclastic cytokine receptor activator of NF-ĸB ligand and inhibitors of the pro -osteoblastic Wnt signaling pathway, which have led to the development of targeted therapies to counteract not only inflammation-induced bone loss but also postmenopausal osteoporosis and osteoporeosis associated with aging. Expand
Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats
TLDR
It is demonstrated that, like their human counterparts, HIV-1 transgenic rats undergo severe osteoclastic bone resorption, a consequence of an imbalance in the ratio of receptor activator of NF-κB ligand, the key osteoclastogenic cytokine, to that of its physiological decoy receptor osteoprotegerin. Expand
Mechanistic insight into osteoclast differentiation in osteoimmunology
TLDR
The importance of the ITAM-mediated costimulatory signals in RANKL-induced osteoclast differentiation is established, which is analogous to the role of costimulation signals in the immune system. Expand
Bone resorption correlates with the frequency of CD5⁺ B cells in the blood of patients with rheumatoid arthritis.
TLDR
It is found that the CD5(+) B cell population is associated with bone resorption as measured via serum CTX-1 levels in a cross-sectional cohort of RA patients, however, a possible functional link between CD5 (+) B cells and bone Resorption still needs to be defined. Expand
...
1
2
3
4
5
...